elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q35648000-E861074A-B8E8-4E35-B403-50C81F05D50E
Q35648000-E861074A-B8E8-4E35-B403-50C81F05D50E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35648000-E861074A-B8E8-4E35-B403-50C81F05D50E
Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study.
P2860
Q35648000-E861074A-B8E8-4E35-B403-50C81F05D50E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35648000-E861074A-B8E8-4E35-B403-50C81F05D50E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
15797d2c087e0b0940251d2066d23eb28b9d24bb
P2860
Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis.